rc-3095

RC-3095, a selective GRPR antagonist, has been shown to have anti-inflammatory properties in different models of inflammation.

RC-3095 TFA (RC-3095 (TFA)) is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.

RC-3095 acetate is an antagonist of bombesin/gastrin-releasing peptide receptor (GRPR). It exerts protective effects by reducing gastric oxidative injury in the arthritic mice.

Neuromedin C is a bombesin-like neuropeptide that stimulates uterine smooth muscle contraction and the release of gastrin , somatostatin, and amylase in rats. Neuromedin C is a truncated form of gastrin-releasing peptide corresponding to the GRP amino acids 18-27. It inhibits GRP and bombesin binding to rat pancreatic membranes (IC50s = 0.4 and 2.2 nM, respectively), which can be reduced by sodium chloride and guanylyl imidodiphosphate . Neuromedin C induces scratching and mast cell degranulation in mice when administered intradermally at doses ranging from 1 to 300 nmol/site, which is inhibited by the BB2 bombesin receptor agonist RC-3095 and reduced in mast cell-deficient mice. Neuromedin C (3.2 nmol/kg, i.p.) reduces rat glucose consumption by approximately 50% for up to one hour.